Case Report

Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF

Figure 1

Proposed mechanism of action of PF-3512676. In the first phase, PF-3512676 activates a rapid induction of innate immune response through TLR9 stimulation in B cell and plasmocytoid cells. This may restore defective plasmocytoid dendritic cell function, induces IFN secretion (all IFN types), and activates NK and NKT cell. A later induction of adaptive immune response may then occur through dendritic cell mediated activation of antigen-specific T cells, monocytes and polymorphonuclear leukocytes, promotion of killer T cells and production of antibodies by B cells.
732680.fig.001